Eastman Kodak Co’s new chief executive, George Fisher, is moving to dismantle his predecessor’s diversification strategy: the company is to divest its Sterling Winthrop Inc pharmaceutical and consumer health products unit and other divisions to focus exclusively on its film and electronic imaging businesses; units to be sold currently generate about $3,700m in annual revenues; it is retaining its X-ray film- and electronics-based medical, cardiology, and dental diagnostic imaging.
FISHER DISMANTLES KODAK DIVERSIFICATION STRATEGY
